STOCKHOLM, SWEDEN--(Marketwire - May 06, 2010) - Swedish Orphan Biovitrum (STO: BVT) today presents as a poster clinical phase II results from the first study showing that Kiobrina® added to infant formula significantly improve growth of preterm infants as compared to placebo after 1 week of treatment. The poster is presented at “The Power of Programming 2010. International conference on developmental origins of health and disease” in Munich, Germany.
Please find the poster enclosed.
“This is an interesting project and Kiobrina holds a great opportunity to fill a medical need in neonatal care. Based on these results and those from a second clinical phase II trial of Kiobrina in pasteurized mother’s milk we are now planning for a phase III study in preterm infants”, said Peter Edman, CSO of Swedish Orphan Biovitrum.
About Kiobrina
Kiobrina is a recombinant human bile-salt-stimulated lipase (rhBSSL) developed by Swedish Orphan Biovitrum, aiming to improve growth and development in preterm infants. The rationale for adding rhBSSL to pasteurized breast milk or infant formula is to restore the natural lipase activity level that is either lost on pasteurization or totally absent in formula.
About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading company focused on treatment of rare diseases.
Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company with an international market presence. The company is focused on providing and developing orphan and niche specialist pharmaceuticals to patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipeline within rare diseases. Swedish Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: BVT) is listed on NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com.
For more information please contact: Swedish Orphan Biovitrum: Peter Edman, CSO Phone. +46 8 697 21 77 Erik Kinnman, EVP Investor Relations Phone: +46 73 422 15 40 erik.kinnman@biovitrum.com Martin Nicklasson, CEO Phone: +46 8 697 20 00 The clinical phase II studies have been carried out partially with research funding from the European Community’s Sixth Framework Program (The Early Nutrition Programming Project, www.metabolic-programming.org). The press release reflects only the author’s views and does not necessarily reflect the views of the European Community or European Commission or their future policy, and they are not liable for any use that may be made of the information contained herein. The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability.
Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on May 6, 2010 at 8:30 a.m. CET.
[HUG#1412421]
Press release in PDF format: http://hugin.info/134557/R/1412421/364686.pdf
Poster Kiobrina clinical phase II results: http://hugin.info/134557/R/1412421/364689.pdf
